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Abstract
Background: P53 activation can trigger various outcomes, among them reversible growth arrest or cellular senescence. It is
a live debate whether these outcomes are influenced by quantitative or qualitative mechanisms. Furthermore, the relative
contribution of p53 to Ras-induced senescence is also matter of controversy.
Methodology/Principal Findings: This study compared situations in which different signals drove senescence with
increasing levels of p53 activation. The study revealed that the levels of p53 activation do not determine the outcome of the
response. This is further confirmed by the clustering of transcriptional patterns into two broad groups: p53-activated or p53-
inactivated, i.e., growth and cellular arrest/senescence. Furthermore, while p53-dependent transcription decreases after 24
hrs in the presence of active p53, senescence continues. Maintaining cells in the arrested state for long periods does not
switch reversible arrest to cellular senescence. Together, these data suggest that a Ras-dependent, p53-independent,
second signal is necessary to induce senescence. This study tested whether PPP1CA (the catalytic subunit of PP1a), recently
identified as contributing to Ras-induced senescence, might be this second signal. PPP1CA is induced by Ras; its inactivation
inhibits Ras-induced senescence, presumably by inhibiting pRb dephosphorylation. Finally, PPP1CA seems to strongly co-
localize with pRb only during senescence.
Conclusions: The levels of p53 activation do not determine the outcome of the response. Rather, p53 activity seems to act
as a necessary but not sufficient condition for senescence to arise. Maintaining cells in the arrested state for long periods
does not switch reversible arrest to cellular senescence. PPP1CA is induced by Ras; its inactivation inhibits Ras-induced
senescence, presumably by inhibiting pRb dephosphorylation. Finally, PPP1CA seems to strongly co-localize with pRb only
during senescence, suggesting that PP1a activation during senescence may be the second signal contributing to the
irreversibility of the senescent phenotype.
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Introduction
Among the different methods cells have to monitor external or
internal stresses, the surveillance mechanism associated with the
p53 gene is central. Numerous molecular studies over the years
have presented p53 as an essential controller of cellular and
genome integrity [1]. p53 is a master transcription factor,
functionally inactive under normal conditions due to its rapid
degradation by the ubiquitin ligase MDM2. A chain of events
triggered in response to cellular stress upsets this precise balance,
leading to the uncoupling of MDM2-driven degradation and to
the ultimate accumulation and activation of p53 [2]. p53 works
mostly as a transcriptional activator, with few molecules in each
cell [3]. However, p53 might also act as a repressor in some
instances [4]. The p53 transcriptional program includes the
activation of a number of cell cycle inhibitors and proapoptotic
proteins, which results in apoptosis, reversible proliferative arrest
or cellular senescence [5,6,7].
In principle, the various outcomes of p53 activation might be
influenced by quantitative or qualitative mechanisms [8]. Some
studies suggest that the level of p53 output determines whether
cells will enter cell cycle arrest or apoptosis. Consistent with this
view, only a subset of the genes induced by high p53 levels are
induced by lower p53 levels [9]. Introduction of high p53 levels
into tumor cell lines induces apoptosis, while the introduction of
lower levels induces only cell cycle arrest [10]. However, other
studies suggest that the outcome of p53 activation is determined by
factors controlled by the tissue type or by the cell genotype.
Oncogenic Ras can activate p53 to promote cellular senescence,
limiting the transforming potential of excessive signalling [11–16].
This study and others have demonstrated that conditional
activation of p53 in mouse embryonic fibroblast cells (MEFs)
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3230produces reversible cell cycle arrest, whereas activation of p53 in
the presence of oncogenic Ras leads to a permanent cell cycle
arrest with features of cellular senescence [17,18]. Although
oncogenic Ras may increase p53 levels, it is not clear whether this
increase is sufficient to explain the induction of senescence.
Two different, though not mutually exclusive, models have been
proposed to explain the different biological outcomes associated
with p53 activation. The quantitative model implies that p53 levels
are sufficient to determine the outcome. Thus, low p53 levels
induce a reversible cell cycle arrest while higher p53 levels induce
senescence or apoptosis. This model is supported by studies in
which p53 levels may be artificially controlled with the appropriate
expression systems [9,10]. One potential mechanism that could
explain such an effect is based on differential p53 affinity for p53
response elements, such that genes required for a reversible cell
cycle arrest have protein products with greater affinities than those
required for senescence or apoptosis.
A qualitative model of p53 action implies that non-quantitative
factors controlled by a stimulus, either the tissue origin or the cell
genotype influence the outcome of p53 activation. Again, two non-
mutually exclusive mechanisms might support the published data.
First, certain collateral signals might directly modulate p53 activity
by changing the conformation of p53 or its association with
various coactivators, perhaps leading to the expression of different
subsets of p53 target genes. Consistent with this possibility,
ionizing radiation and UV light have been shown to induce
expression of different subsets of p53-dependent target genes in the
same cell type [9]. Interestingly, these two stimuli induce different
p53 modifications [19–21], raising the possibility that the
activating signal may modulate p53 activity in a qualitative
manner by directing p53 to different promoters [22]. Similarly, the
ability of oncogenes to promote either apoptosis or senescence is
correlated with different p53 modifications.
Furthermore, oncogenic Ras induces p53 phosphorylation on
serine 15 and induces senescence, whereas the E1A oncoprotein
does not induce serine 15 phosphorylation and promotes apoptosis.
The E1A effect is dominant, since cells coexpressing E1A and Ras
do not contain p53 that has been phosphorylated on serine 15, and
these cells are prone to apoptosis [23,24]. Whether this effect leads
to the expression of different p53 target genes has yet to be
determined. Second, it is possible that the signal produced by p53
activation is the same in different contexts and that the outcome of
p53 activation is determined by how this signal is interpreted by the
cell. One may envision several mechanisms by which this might
occur, but an obvious possibility involves the combined action of
p53 and other transcription factors such that the action of p53 on
outcome-specific targets is influenced by the presence or absence of
these other factors. These other factors, in turn, would be the targets
for the hypothetical collateral signal. One precedent forthisinvolves
the integrationof p53 and interferonsignalingon the p21promoter,
which contains both p53 and IRF-1 response elements that act to
synergistically induce p21 expression during a DNA damage
response [25]. How different signal transduction pathways integrate
to produce new biological outcomes is an important biological
problem that may also have an impact on the understanding of p53.
How does oncogenic Ras convert p53 to a senescence inducer?
Although it seems likely that a component of this response results
from the ability of oncogenic Ras to produce quantitative increases
in p53 activity via ARF-mediated inhibition of MDM2, there is
compelling evidence for collateral signals that modify the outcome
of p53 activation leading to senescence [17,26]. Following the
discussion above, it is formally possible that oncogenic Ras directly
modulates p53 activity or, instead, produces cellular changes that
reinterpret the p53 signal.
One potential mechanism may involve the ability of Ras to
induce PPP1CA (the catalytic subunit of PP1a) expression,
regulating senescence in a pRb-dependent manner [18]. pRb is
involved in the SAHF, maintaining long-term inhibition of E2F-
dependent transcription through changes in the packaging status
of chromatin [27].
To characterize the p53 response during growth arrest and
senescence, this series of experiments compares p53-dependent
transcription in different situations involving proliferation, revers-
ible arrest, replicative senescence or Ras-induced senescence.
Results
p53 levels and phenotype
To assess if differences in p53-dependent transcription play a
role in reversible arrest or senescence, this study took advantage of
the mouse embryo fibroblast (MEF) cell system that allows easy
manipulation of cellular stresses in otherwise homogeneous
conditions. For instance, conditional activation of the p53 pathway
in MEFs is known to trigger reversible cell cycle arrest, whereas
activation of p53 in the presence of oncogenic Ras leads to
permanent cell cycle arrest with features of replicative senescence
(Figure 1A) [16].
To induce replicative senescence, wild-type and p53-null (p53
2/2) embryos were generated from crosses between heterozygous
p53 knock-out mice. From wild-type embryos, MEFs were
generated and grown until replicative senescence was reached
(approximately at passage 5, corresponding to 10 population
doublings). We extracted mRNA under these conditions, i.e.,
terminally arrested with senescence features (P5), and also from
exponentially growing MEFs (early passage, P3). Other stress
conditions leading to senescence were produced as follows. Wild-
type MEFs growing at early passage were infected with
retroviruses carrying oncogenic Ras (Val12-Hras). Cells were
selected for retrovirus insertion and once they reached senescence
(corresponding to approximately passage 3), mRNA was extracted
(P3+ras). P53-null MEFs were infected with viruses carrying the
135V thermosensitive mutant of p53 that induces cellular arrest at
permissive temperature (32u) [28]. These cells (p53ts), while
maintained at restrictive temperature (39uC), were infected with
viruses carrying oncogenic Ras (p53ts-ras), which induces
senescence when shifted to permissive temperature [17]. For a
summary of conditions and the resulting phenotypes see Table 1.
The abundance of p53 did not change among different passages
reaching replicative senescence, or between the restrictive or
permissive status in the case of the overexpression of the
thermosensitive mutant of p53 (Figure 1C). Therefore, this study
first measured broad p53-dependent transcription (Figure 1B). We
measured the expression of 122 p53 target genes using Dot Blot
arrays in the different proliferating and arrested cellular scenarios
discussed above (See Figure S1 for a list of the 122 genes analyzed).
The increased transcription rates of important p53 target genes
such as Bax, GADD45, p21 and PIG8 confirm the activation of
p53 in both senescence systems (Figure 1C).
We observed that the arrest of MEFs at senescence (P5) and after
Ras-induced senescence (P3+ras) correlated with a net increase in
p53-dependent transcription (Figure 2A). Similarly, cells arrested
after p53 activation (ts and ts-Ras at 32uC)alsoshowed,asexpected,a
significant increase in p53-dependent transcription (Figure 2A).
Therefore, we had a genetically homogeneous system with different
levelsofp53activitymeasured with respect to122p53transcriptional
targets. It was possible to ascribe a phenotype to each level of p53
activity (Table 1). There were three conditions of proliferating cells:
(1) P3, (2) cells with mutant p53 at restrictive temperature (null p53),
p53 Response to Senescence
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condition of replicative senescence with a moderate increase of p53
activity (P5). Oncogenic Ras activation seems to induce higher levels
of p53 activation with similar senescent phenotypes (P3+ras).
However, elevated levels of p53 do not always induce senescence as
p53ts cells at permissive temperature are reversibly arrested, but p53
activity is higher than in the two previous conditions displaying
senescence. As before, oncogenic Ras expression switches the cell
from arrest to senescence, also increasing the relative p53-dependent
transcription (Table 1 and Figure 2A).
Figure 1. Experimental system. A) Molecular markers used to identify senescence. B) Scheme of the procedure (see M & M) and 2 representative
images of the dot blot obtained after hybridization. C) Comparison of several conditions of well-known activated targets of p53. Western blot
showed no variation among p53 levels under comparable conditions.
doi:10.1371/journal.pone.0003230.g001
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relative levels of p53 activity alone.
Specificity of the senescence response
To study the expression pattern of p53-responsive genes during
arrest or senescence in order to compare both processes and to
ascertain what gene or genes may play a crucial role in the
proliferating or arrested cell phenotypes, we performed a
hierarchical clustering of the different cellular conditions on the
basis of pattern similarity (see Materials and Methods). In
Figures 2B and 2C we observed that the conditions are separated
into two groups corresponding to the arrested (right side) and
proliferating (left side) phenotypes. The cell lines are grouped
together on the cluster dendogram by the activation or
inactivation of p53 and not by the presence or absence of the
Ras oncogene. This is clear in wild-type MEFs growing at passage
3 (P3), which have low levels of p53 activation compared to
arrested wild-type MEFs in passage 5 (P5), which have p53 highly
activated. However, it is interesting that the most extreme
condition, p53 activation in the presence of oncogenic Ras,
triggers an enhanced transcriptional response (Figures 2A and 2C,
lane p53ts-Ras [32u]). See below.
Although all the physiological conditions that lead to growth-
arrest onset are clustered together and all the transcripts
considered are p53-dependent, it is clear that there are some
genes whose enhanced activation (relative to their median
expression level over all cellular conditions) is specific to each
particular condition (Figure 2C and Table 2). These genes might
serve as specific marker genes. However, no concurrent senescence
signature could be observed, indicating that the senescence
program is not determined by the specificity of the p53 response.
Next, applying a penalized least-squares regression technique
with an L1-type penalty to the expression data (see Materials and
Methods) it was possible to identify four p53 target genes among
the 122 genes studied as the most relevant markers for predicting
the proliferating or arrested phenotype of each cellular condition.
These four relevant genes are: MAP4, PTEN, Lats2 and Rb1
(Figure 2D). Furthermore, combining L1- and L2-norm penalties
allowed small subgroups of additional genes that are highly
correlated with the main predictors to be extracted. This study
identified five more genes closely related to MAP4 behavior: p63,
caspase1, DKK1, Bcl2 and Gtse1; as well as LRDD, related to
Rb1. This robust set of p53 target genes molecularly defines a
minimal footprint to identify a p53-dependent arrest.
In order to confirm the p53-dependent arrest footprint defined
by these markers, we measured the p53-dependent transactivation
of 4 among the selected genes by qRT-PCR in HCT 116 p53+/+
cells treated with different DNA-damaging agents. p53 protein is
present at low levels in resting cells but after exposure to those
agents as well as to other stressing stimuli, it is stabilized and
activated by a series of post-translational modifications. These
modifications leave p53 free from mdm2, an E3 ubiquitin ligase
that ubiquitinates it and facilitates its degradation by the
proteasome [5]. p53 stabilization and activation is followed by
cell-cycle arrest. To ascertain whether the transcription of this set
of genes also depends on other chemotherapeutic drugs that act
through p53-independent mechanisms, we also treated the cells
with compounds that do not directly cause DNA breaks. Only the
treatment with the topoisomerase inhibitors Etoposide and
Doxorubicin induced an activation of the transcription of PTEN,
Lats2, Rb1 and MAP4 (Figure 2E). However, we did not detect
increase of these genes by Taxol, flavopiridol or UCN-01.
Downregulation of p53 response without senescence
P53 transcription seems to define only arrest, and not senescence,
suggesting the existence of a p53-independent signal necessary to
convert the reversible arrest into senescence. To explore this, we
analyzed whether sustained p53 activation might induce senescence
without a second signal. In the same p53-induced transcriptional
setting,weanalyzedtheactivationofp53duringlongperiodsand its
correlation with the appearance of senescence. After an initial
activation, general p53-induced transcription seems to decay at 24
hrs; this downregulation is maintained for long periods even in the
presence of Ras activation (Figure 3A). However, senescence
features are only maintained in the p53ts-Ras cells incubated at
32uC (Figure 3B). We found that in cells carrying activated p53
only, senescence is not induced despite a long period of growth
arrest (up to 6 days). These data support the finding of Ferbeyre et
al. [17], that growth arrest and senescence are two independent
phenotypes; the permanence of growth arrest does not induce
senescence unless another signal is involved.
Finally, to confirm that the cells in long-term arrest have not
suffered molecular changes that might indicate a switch to
senescence, we analyzed 53BP1 and cH2AX phosphorylation at
the senescence-associated DNA foci. As before, p53ts and p53ts-
Ras cells were cultured at 39uC, then were moved to 32uC and
maintained for up to 6 days at restrictive temperature. Cells were
taken at different time points and analyzed for the presence of
DNA-damage foci labeled by 53BP1 and cH2AX phosphorylation
as markers for cellular senescence (Figure 4). One or two 53BP1
and cH2AX foci appear with cell proliferation, and the same
number of foci was maintained in p53ts arrested cells even after 6
days of growth arrest. However, p53ts-Ras cells showed a strong
increase in the number of foci per nuclei after 48 hrs of arrest
(Figure 4); this was maintained despite p53-transcriptional
downregulation.
These data, which are consistent with previous observations
[17,26], indicate that initial p53 activation is required to induce
Table 1. Summary of cell lines and conditions used in this study.
Cell line Genotype phenotype
p532/2 p532/2 MEFs Growth at 32u and 39u
p532/2;ts (p53ts) p532/2 MEFs with p53val135 Growth at 39u reversible arrest at 32u
p532/2;ts-ras (p53ts-ras) p532/2 MEFs with p53val135 Growth at 39u; senescence at 32u
p3 naı ¨ve MEFs, 6 population doublings Growth at 37u
p5 naı ¨ve MEFs, 10 population doublings senescence at 37u
P3+Ras (Ras) naı ¨ve MEFs+Ras-val12, 6 population doublings senescence at 37u
doi:10.1371/journal.pone.0003230.t001
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PLoS ONE | www.plosone.org 4 September 2008 | Volume 3 | Issue 9 | e3230Figure 2. Analysis of the p53-dependent transcriptional signature. A) Comparison of the levels of 122 transcriptional targets of p53 at
different conditions of p53 activity. See text. Data normalized against b-actin were compared to the proliferative condition P3 to evaluate its statistical
significance. Statistical analysis was performed by paired t-test. (*)=p,0.05; (**)=p,0.005; (***)=p,0.001. B) and C) Analysis of the expression
values of 122 transcriptional targets of p53 under different cellular conditions, which led either to proliferation or to growth arrest. Clustering analysis.
Hierarchical clustering was performed using the function hcluster (package amap) of the free statistical software R. See M & M. The expression level of
each gene, relative to its median expression level across all conditions, was represented by a color, with red representing expression greater than the
median, green representing expression less than the median, and the color intensity representing the magnitude of the deviation from the median.
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be required to stabilize the arrest as irreversible senescence.
PPP1CA contributes to growth arrest stabilization in
senescence
The application of a retroviral-based genetic screen yielded an
antisense RNA fragment against PPP1CA, the catalytic subunit of
PP1a. Loss of PPP1CA function bypasses Ras/p53-induced
growth arrest and senescence [18]. It was found that oncogenic
Ras promotes an increase in the intracellular level of ceramides,
which may increase PPP1CA activity, contributing to senescence.
PP1a has been identified as the protein phosphatase responsible
for the dephosphorylation of pRb [29]; this has been related to the
growth arrest response [30–32]. When cells are actively growing,
the hyperphosphorylated form of the Rb protein (ppRb)
predominates. On the contrary, when cells are delayed in their
growth, the hypophosphorylated form of the Rb protein (pRb) is
the most abundant. Thus, enforced pRb dephosphorylation might
contribute to the arrest to senescence transition [27,33].
PPP1CA protein levels increase upon Ras activation (Figure 5A)
[34,18], but not mRNA (Figure 5B). PP1 phosphatase activity also
increases upon oncogenic ras expression (Figure 5C), paralleling
protein levels of PPP1CA. Expression of a specific shRNA against
PPP1CA impairs pRb dephosphorylation, thus bypassing p53-
induced arrest. When p53ts-Ras cells were shifted at 32uC, pRb
became hypophosphorylated, in accordance with the growth-
arrest induced by thermo-sensitive p53 at this permissive
temperature. In contrast, p53ts-Ras cells stably transduced with
shRNA against PPP1CA showed an increase in the hyperpho-
sphorylated form of Rb protein when kept for 24 h at 32uC
(Figure 5D). These data show that downregulation of PPP1CA
maintains pRb in the hyperphosphorylated state, even in the
presence of active p53, therefore allowing cell growth (Figures 5D
and 5E). While p53ts-Ras cells at 32uC show mostly the senescent
phenotype, only 22% of cells carrying the PPP1CA shRNA
showed senescence features, confirming the relevance of PP1a
activity to the senescence phenotype (Figure 5F). This was further
confirmed by immunofluorescence studies (Figure 6). In prolifer-
ating cells, PPP1CA and pRb levels are low, increasing slightly
upon growth arrest. However, these proteins showed diffuse
distribution (Figure 6). Under conditions inducing senescence
(p53ts-Ras at 32uC), cells increase pRb and PPP1CA levels, which
showed nuclear co-localization, strengthening evidence for their
functional relationship to senescence.
Oncogenic stress enhances p53-dependent transcription
We also observed that oncogenic Ras enhances p53-dependent
transcription (Figures 2A and 2C). To study this effect in detail, we
selected three different p53-responsive promoters, Bax, p21waf1
and the synthetic p53 response element (x13). We engineered a
construct fusing the different promoters 59 of the luciferase
reporter gene and compared the effect of p53 alone to the effect of
the combination of p53 and Ras-val12 (Figure 7A). Oncogenic
Ras enhances p53-dependent transcription in all cases, but does
not alter transcription when transfected alone (Figure 7A). These
effects are dependent on p53 and Ras doses (Figure S2).
To further study this effect, we selected the Bax promoter and
investigated dependence of the phenomenon on Ras. To that end,
we tested the N17 mutant of Hras-val12. This mutant lacks the
ability to bind to Ras effectors and therefore acts as a dominant
negative mutant. The N17 mutant does not alter the p53 response
(Figure 7A), indicating that the Ras effect is dependent upon
activation of Ras effectors. To directly discriminate between the
two main effector pathways involved in this effect, the same
experiment was performed with active PI3K or Raf pathway
mutants. We co-transfected p53 and an active mutant of AKT
(AKT-CA) (PI3K pathway), or an active mutant of Raf (BXB-Raf-
CAAX). We were able to reproduce the ras-enhancing effect
(Figure 7B), indicating that a strong activation of either pathway
may provoke the enhancement of p53 transcription.
Ras, acting through the Raf pathway, may activate p53 through
p19ARF, either dependent upon or independently of MDM2,
while PI3K may inhibit p53 through MDM2 phosphorylation
[7,35,36]. To determine whether MDM2 or p19 was involved in
the effect, the experiment was performed in p19-null or MDM2-
null cells (Figure 7C). We observed that the p53-enhancing effect
observed in the Ras oncogenic signal was dependent upon
p19ARF but not on MDM2. A similar observation was made
with the activated Raf oncogene. However, activated AKT
showed p53-enhancing effects independent of p19ARF and
Table 2. Condition-specific genes.
P5 Replicative Ras Oncogenic Stress
p53ts(32u) Growth
arrest
IGF-R p63 GML
MAP4 CycB1 Bak
ZAP70 Krt2-8 Bax
Wig1 Krt1-15 PTGF
PIG8 Pmaip1 Igfbp6
IL6 DKK1 Bcl6
P73 PUMA PPM1D
Lats2 Mgmt Tyr
Bax Pold1 MDR1
Jun Lats2 Thbs1
LRDD/PIDD Kai1
Pthlh Btg2
Waf1 MAP4
Igfbp3 Tst
MST1 RB1
RB1 IGFR
Hic1 p14-ARF
This table represents the genes that are the most representative (relative to
their median level–based on all conditions) in each particular arrested
condition. A threshold equal to 2.30 was chosen for the ratio. Genes are
arranged from the lowest to highest ratio.
doi:10.1371/journal.pone.0003230.t002
D) Feature selection. Since the number of genes is much greater than the number of conditions, we used penalized regression methods. See text and
M & M for more details. E) Validation of the feature selection by quantitative PCR. See text and M&M. We determined Lats2, DKK1, pRb and PTEN
mRNA levels after 24 hts treatment of HCT116 cells with the indicated treatment, by quantitative PCR. Cyclophilin (ref. 4326316E), an endogenous
control, was used to normalize variations in cDNA quantities from different samples. Each reaction was performed in triplicate with cDNA from
normal and tumor tissue from each patient studied. C shows untreated samples. E: Etoposide, D: Doxorubicin, T:Taxol, U: UCN-01, F:Flavopiridol. Data
shows average of three determinations.
doi:10.1371/journal.pone.0003230.g002
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[11,37–39]; Ras and Raf oncogenes require the p19ARF protein
to activate p53.
Discussion
The data presented in this study elucidate the regulation of p53-
responsive genes during proliferation and senescence. We have
clearly demonstrated that Ras effects on p53-dependent transcrip-
tional activation result in quantitative rather than qualitative
changes. Therefore, the senescence response depends on factors
other than p53 activation. p53 activation seems to be necessary but
not sufficient to induce senescence, as other signals may be needed
for the full onset of senescence. We have shown that Ras-induced
activation of PPP1CA, the catalytic subunit of PP1a, is necessary to
induce Ras-dependent senescence [18]. It is therefore possible to
split the senescence response into two physiological processes. The
first of these involves induction of growth arrest and is dependent on
p53 activation or other physiological signals activating a prolifer-
ative brake similar to that of p53, such as p73 or p63. The second
Figure 3. P53 activity is downregulated maintaining senescence. Cells were plated in 10-cm-diameter plates. Cells were grown at 39uC (i.e.,
never incubated at 32uC) or arrested for the indicated times at 32uC. Cells were harvested and RNA collected for A, or stained for SA b-GAL for B. A)
Comparison of the levels of 122 transcriptional targets of p53 at different times after p53 activation. Data normalized against b-actin was compared to
the proliferative conditions at 39uC to evaluate statistical significance. Statistical analysis was performed by paired t-test. (*)=p,0.05; (**)=p,0.005;
(***)=p,0.001. B) More than 400 cells were visually analyzed for SA b-GAL staining as described in Figure 1A. Data represent the percentage of cells
showing SA b-GAL staining.
doi:10.1371/journal.pone.0003230.g003
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sphorylated form, independent of p53. Unphosphorylated pRb will
bind and inactivate E2F factors blocking cell cycle progression and
altering local chromatin [27]. PPP1CA activation will take part in
this second process, contributing to irreversible proliferative arrest
by enforcing pRb dephosphorylation.
Figure 4. Enforced growth arrest does not induce senescence. P53ts or p53ts-Ras cells were grown at 39uC or incubated at 32uC for different
times as indicated. Cells were fixed and stained with DAPI to identify the nuclei, or with antibodies against 53BP1 or phosphorylated gH2AH. A)
Representative picture. B) Foci of .60 nuclei of each condition were counted and data represented as the average of the number of foci per nuclei.
Bars=StDev.
doi:10.1371/journal.pone.0003230.g004
p53 Response to Senescence
PLoS ONE | www.plosone.org 8 September 2008 | Volume 3 | Issue 9 | e3230Figure 5. A) Oncogenic Ras increased PPP1CA protein levels. P53ts (control) or p53ts-Ras (+ras) cells were grown at 39uC or incubated at 32uC for 24
hrs. Then PPP1CA protein levels were analyzed by western Blot. a-tubulin was used as a loading control. The data are representative of three
independent experiments. B) PPP1CA mRNA levels were not dependent on the expression of oncogenic ras. mRNA levels were analyzed by Northern
blot. A labeled probe able to specifically recognize PPP1CA isoform was used as described in M&M. C) Oncogenic ras increased PP1 activity.
Exponentially growing cells were keep growing or switch for 24 hrs at 32uC as indicated. Then were starved and PP1 phosphatase activity was
measured as described in M&M. C shows the remaining activity after 100 nM okadaic acid treatment to inhibit PP1 and PP2A activity. D, E, and F)
P53ts-Ras cells carrying the shRNA against PPP1CA (shRNA) or vector alone (control) were grown at restricted temperature (39uC), or permissive
temperature (32uC) as indicated, for 24 hrs. Cells were harvested for protein extraction (for D), fixed and stained with crystal violet (for E) or for SA b-
GAL (for F). D) Downregulation of PPP1CA inhibits p53-induced pRb hypophosphorylation. Cells were processed for western blot,
showing hyperphosphorylated (ppRb) and hypophosphorylated (pRb) forms of the protein. a-tubulin was used as a loading control. The data are
representative of three independent experiments. Bottom panel shows quantification of pRb bands. E) and F) Downregulation of PPP1CA
bypasses p53/ras-induced senescence. Cells (10
4) were seeded and grown at 39u or 32uC for 1 week, then fixed and stained for colony formation
with crystal violet (E) or SA b-GAL (F). In F, numbers show the percentage of cells with SA b-GAL staining.
doi:10.1371/journal.pone.0003230.g005
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pretumoral cells from further expansion, many studies have
recently emphasized the relevance of this possible new therapeutic
tool against cancer (reviewed in [41–43]). Our work has identified
a set of p53 target genes that affect growth arrest in response to
p53 activation. Although our work only identify these 4 genes as
the minimal footprint to differentiate growing from p53-arrested
cells, these 4 genes have been broadly studied and its relevance in
growth arrest and senescence has been established.
Tumor suppressor Lats2 has been shown to be necessary for
culture-induced replicative senescence in MEFs, since Lats22/2
MEFs bypass this process [48]. Furthermore, cells lacking Lats2
showed increased prevalence of micronuclei, chromosomal defects
and aneuploidy [48,49]. Lats2 and p53 establish a positive feedback
loop that prevents tetraploidization of cells treated with the
microtubule poison nocodazole [49]. Most important, miRNA-
372 and miRNA373 microRNAs directly target Lats2 expression
and have been shown to cooperate with oncogenic Val12-Ras in a
way that resembles p53 inactivation, acting as oncogenes in
testicular germ cell tumors [50]. Finally, Lats2 has been shown
down-regulated through promoter hypermethylation [51,52], in
association with poor prognosis human breast cancers and acute
lymphoblastic leukemia. Lats2 might have a role against cancer
development, probably through the induction of senescence, and
this could explain the link between its down-regulation and tumoral
progression. The tumor-suppressor gene RB1 can suppress S phase
entry and cause a transient G1 arrest following DNA damage [53–
55] and the mutations in Rb1 pathway-related genes are associated
with poor prognosis in many tumor types. The PTEN/PI3K
pathway is also regarded as an effector of cellular senescence [56]
through p27kip1 cell cycle inhibitor activation.
The key findings obtained in this study may contribute to the
current understanding of the molecular basis of senescence and
should be of great interest in future senescence studies.
Materials and Methods
Cell Culture
Primary MEFs from p532/2 mice were derived from day 13.5
embryos. Cells expressing murine p53val135 were generated by
retrovirus-mediated gene transfer of p53val135 into p532/2
MEFs (p532/2 ts). Cells expressing Val12-Ras were generated by
retrovirus-mediated gene transfer of pWZLBlast hVal12-Ras into
wild-type MEFs at passage 3 (P3-Ras) and p532/2 ts (p532/2 ts
Ras cells). Cells were cultured in Dulbecco’s Modified Eagle’s
medium (GIBCO) supplemented with 10% fetal bovine serum
(Sigma), 1% penicillin G- streptomycin sulfate (GIBCO), 0.5%
fungizone-amphotericin B (GIBCO) and 5 mg/ml plasmocin
(InvivoGen).
P532/2 MEFs, p532/2 MDM22/2 MEFs and p192/2
MEFs were cultured in Dulbeccos Modified Eagles medium
(GIBCO). All media was supplemented with 10% fetal bovine
serum (Sigma), 1% penicillin G-streptomycin sulphate (GIBCO),
and 0.5% fungizone-amphotericin B (GIBCO) in a humidified
CO2 incubator at 37uC.
Retroviral Vectors and Gene Transfer
The following retroviral vectors were used: p53val135 mutant
cDNA in pWZLHygro and pWZLBlast hVal12-Ras. Retrovirus-
mediated gene transfer was performed as previously described
[44]. Briefly, 5610
6 LinXE retrovirus producer cells were plated
in a 10 cm dish, incubated for 24 h and then transfected by
calcium-phosphate precipitation with 20 mg of retroviral plasmid
(16 h at 37uC). The medium was changed and the plates were
maintained at 32uC for 48 h to increase viral stability. Virus-
containing supernatant was filtered through a 0.45 mm filter and
supplemented with 8 mg/ml polybrene (Sigma) and an equal
volume of fresh medium. Prior to infection, 8610
5 target
fibroblasts were plated per 10 cm dish and incubated for 24 h.
Figure 6. PPP1CA and pRB co-localize during p53/ras-induced senescence. P53ts or p53ts-Ras were grown at 39uC or incubated at 32uC for
24 hrs. Cells were fixed and labeled with DAPI to identify the nuclei, as well as antibodies against PPP1CA (red) or pRb (green).
doi:10.1371/journal.pone.0003230.g006
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supernatant, and then the culture plates were centrifuged (1 h at
1,500 rpm) and incubated at 37uC for 16 h. The medium was
changed and cells were split 24 h later. Infected cell populations
were selected in hygromycin (20 mg/ml) for pWZLHygro-based
vectors and in blasticidin (2 mg/ml) for pWZLBlast-based vectors.
Northern assays
Total RNA was isolated from cells using the TRI-REAGENT
method (Molecular Research Center, Cincinnati, OH) according
to the manufacturers instructions. A reverse transcription was
done for each sample (20 mg of total RNA) using MMLV reverse
transcriptase (Promega), oligo dT primer and dCTP
32-labeling
nucleotide.
The cDNA
32P-labeled probes were hybridized to the p53 target
gene array membrane (TranSignal, Panomics, CA, USA) at 42uC
overnight. After removing excess substrate by gently washing twice
with 26SSC+0.5% SDS and 0.16SSC+0.5% SDS at 62uC, the
membranes were exposed to BioMax Films (Eastman Kodak
Company, NY, USA). The assay normalization was done selecting
b-actin as the control housekeeping gene. Analysis was done using
the GS-800 Calibrated DensitometerH and the Quantity OneH
program from Bio-Rad.
Each experiment for each condition was performed indepen-
dently at least twice, the data quantified and normalized for the
value of b-actin (a gene with transcription that is independent of
p53).
Raw data for all conditions were normalized against an internal
control, b-actin, and then compared to normal proliferating
MEFs.
PPP1CA Northern Blot. Total RNA was extracted using
RNAzolB. 10 mg of total RNA were run in formaldehyde-agarose
gels and transferred to a Hybond membranes. The membrane was
pre-hybridized during 4 hours at 65uC. The probe was labeled by
Figure 7. Oncogenic Ras enhances p53-transcriptional activation. A, B and C) p53(2/2), p53(2/2); MDM2(2/2) or p19(2/2) MEFs were
transfected as indicated with plasmids carrying luciferase and the indicated genes. Luciferase activity was measured as indicated in the M & M. A)
Assays were performed in p53(2/2) MEFs using different promoters responding to p53 (p21waf1, Bax and synthetic p53x13 carrying only the p53
binding site repeated 13 times). B) Only the Bax promoter was used in p53(2/2) MEFs. C) Only the Bax promoter was used in p53(2/2), double
p53(2/2); MDM2(2/2) or p19(2/2) MEFs. Data show the averages of three independent experiments.
doi:10.1371/journal.pone.0003230.g007
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primers for mouse PPP1CA. The purified probe was denatured
and added to the hybridization solution. The hybridization was
performed overnight at 65uC. After extensive whashing, the
membrane was exposed to a Biomax MS film (Kodak).
Data Analysis
The data consisted of the expression values of 122 transcrip-
tional targets of p53 in different cellular conditions, which led
either to proliferation or to growth arrest.
Clustering analysis. Hierarchical clustering was performed
using the function hcluster (package amap) of the free statistical
software R (Ihaka and Gentleman, 1996). Before statistical
analysis, gene expression levels were standardized gene by gene
across all conditions using the median and interquartile range
(IQR). The cellular conditions were clustered using Ward linkage
and uncentered Pearson metric tests. The results were visualized
and analyzed with TreeView (M. Eisen; http://www.microarrays.
org/software). The expression level of each gene, relative to its
median expression level across all conditions, was represented by a
color, with red representing expression greater than the median,
green representing expression less than the median, and color
intensity representing the magnitude of the deviation from the
median.
Feature selection. The problem of extracting a robust set of
predictors for the proliferating status of the different cellular
conditions has been formulated as a least squares regression
problem. Since the number of genes is much larger than the
number of conditions, we used penalized regression methods. The
standard penalty used in so-called ridge regression is given by the
L2-norm of the vector containing the regression coefficients. Such
penalty allows stabilizing the ordinary least squares estimate, but
typically will retain all regression coefficients so that no selection of
the relevant variables (genes) may be done. To perform the
selection task, we used an L1-norm penalty, as is done in lasso
regression. This type of penalty is known indeed to promote
sparsity, i.e., to force many regression coefficients to be zero; this
obviates the need for pre-selection of the data. However, a known
drawback of the L1 penalty for variable selection is that in a group
of highly correlated genes, it may pick up only one representative.
We therefore also used combined L1- and L2-norm penalties to
select sparse groups of highly correlated genes; this is done in the
so-called ‘‘elastic net’’ proposed in Zou and Hastie, 2005, [46]. To
compute the corresponding penalized least-squares solutions, we
applied the iterative thresholding algorithm developed in
Daubechies et al, 2004. [47], which is simple to implement,
robust to measurement errors and works well for high-dimensional
data. Despite the small number of conditions, some standard
validation tests (such as leave-one-out, label and gene permutation,
bootstrap sampling) were performed.
Transcriptional Assays
For transient transfection of cells, we seeded 2–46105 H1299
cells per well in six-well plates. After 24 h, transfections were
performed by the calcium chloride method and JetPEI reagent
(Polytransfection, Illkirch, France) according to the manufacturer’s
recommendations. For both transfection methods, we used 1.5–
2 mg each of the reporter plasmids pGL3-13X, pGL3-Bax and
pGL3-p21 in the presence or absence of pBABE puro p53 wt (0.6–
0.75 mg) and pLSXN Ras val 12, or active mutants of the PI3K or
Raf pathway (0.6–0.75 mg).
Renilla luciferase plasmid was used as an internal control for
transfection efficiency. The total amount of DNA within the
experiments was kept constant by adding empty vector plasmid
DNA to the transfection mixtures.
Reporter gene assays were performed with the Dual-LuciferaseH
Reporter Assay System (Promega, USA) 48 h after transfection
and the results were measured with a Victor2V luminometer. The
activity of the reporter luciferase was expressed relative to the
activity in renilla vector-transfected cells. Similar results were
obtained in at least three different experiments. All results were
compared to the control and are shown in the figures as the
mean6S.D. of independent triplicate cultures.
Western Blot
Cells were prepared in lysis-buffer and proteins were separated
on SDS-PAGE gels, transferred onto PVDF membranes (Im-
mobilon-P, Millipore) and immunostained. The following primary
antibody was used: anti-p53FL393 (Santa Cruz 6243, diluted
1:1000), anti-PP1a (from Calbiochem) anti-Rb: G3-245 from BD
Pharmingen; and horseradish peroxidase-labeled rabbit anti-
mouse (Promega diluted 1:5000) and goat anti-rabbit (Calbiochem
401315, diluted 1:4000) secondary antibodies. Proteins were
visualized using the ECL detection system (Amersham Biosciences,
Buckinghamshire, UK).
Immunofluorescence
Immunostaining and confocal analysis for 53BP1 and
cH2AX foci. Cells were seeded onto glass cover slips and
cultured for 8 h at 39uC. Then we placed the cells at 39uC and
32uC. After 24 h (cells at 39uC and 32uC) and 48 h, 96 h and
144 h (cells at 32uC), cover slips were fixed in 4%
paraformaldehyde for 5 min at room temperature, washed twice
with PBS, permeabilized in Triton X-100 0.5% in PBS for 5 min
and washed twice more with PBS. Samples were incubated in
blocking solution (PBS containing 3% bovine serum albumin) at
37uC for 15 min, followed by incubation for 30 min at 37uC with
anti-phospho-Histone H2A.X (Ser139) antibody (Millipore 05-
636) or anti-53BP1 antibody (Novus Biologicals NB100-304)
diluted 1:100. After washing with PBS, cells were incubated with
species-specific Alexa 488-conjugated secondary antibody diluted
1:100 in blocking buffer for 30 min at 37uC in the dark. The
nuclei were stained with Hoechst 33258 diluted 1:1000 for 3 min
at room temperature in the dark prior to mounting with mowiol
(Calbiochem). Images were collected by confocal laser microscopy
(model TCS-SP2-AOBS, Leica, Germany).
Immunostaining and confocal analysis for PPP1CA and
pRb co-localization. Cells were seeded onto glass cover slips
and cultured for 8 h at 39uC. Then we placed the cells at 39uC
and 32uC. After 24 h (cells at 39uC and 32uC) and 48 h (cells at
32uC), cover slips were fixed in 4% paraformaldehyde for 5 min at
room temperature, washed 2 times with PBS, permeabilized in
Triton X-100 0.5% in PBS for 5 min and washed again 2 times
with PBS. Samples were incubated in blocking solution (PBS
containing 3% bovine serum albumin) at 37uC for 15 min,
followed by incubation for 30 min at 37uC with anti-human
Retinoblastoma Protein (RB) monoclonal antibody (BD
Pharmingen 554136) diluted 1:100. After washing with PBS,
cells were incubated with species-specific Alexa 488-conjugated
secondary antibody diluted 1:100 in blocking buffer for 30 min at
37uC in the dark. Then, cells were incubated with anti-Protein
Phosphatase 1a, C-terminal antibody (Calbiochem 539517)
diluted 1:100. After washing with PBS, cells were incubated with
species-specific Alexa 633-conjugated secondary antibody diluted
1:100 in blocking buffer for 30 min at 37uC in the dark. The
nuclei were stained with Hoechst 33258 diluted 1:1000 for 3 min
at room temperature in the dark prior to mounting with mowiol
p53 Response to Senescence
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(model TCS-SP2-AOBS, Leica, Germany).
SA ß-Gal activity
Senescence-associated (SA) ß-galactosidase (ß-Gal) activity was
measured as previously described [45], except that cells were
incubated in 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside
(XGal) at pH 5.5 to increase the sensitivity of the assay in MEFs.
The percentage of cells expressing SA ß-Gal was quantified by
inspecting .400 cells per 10-cm-diameter plate three times.
Protein phosphatase assays
PP1 activity was determined according to standard procedures
as previously described [57]. PP activity was assayed using 32P-
labeled phosphorylase a as a substrate which detects both PP1 and
PP2A activities. To selectively measure PP1 activity we used 2 nM
okadaic acid to selectively inhibit PP2A. The cell pellet was
homogenized in the extraction buffer containing 20 mM Tris-
HCI, pH 7.5, 5 mM EDTA, 10 mM EGTA, 15 mM -mercap-
toethanol, 0.25 M sucrose, 0.3% Triton X-100, 5 mg/ml leupep-
tin, and 5 mg/ml aprotinin and centrifuged to give a soluble
supernatant. The PP activity in the clear supernatant was
determined by measuring the trichloroacetic acid-soluble counts
released after incubation of the 32P-labeled phosphorylase a in the
cell extract. The PP activity was linear up to assay times of 10 min
and 5 mg protein of the cell extract. Routinely, incubation for PP
activity was carried out for 10 min with an extract containing 5 mg
of protein as determined by the Bio-Rad assay (Bio-Rad, Hercules,
CA). Negative controls were obtained incubating with 100 nM
Okadaic acid to inhibit PP1 and PP2A activity. One unit (U) of
activity is defined as the amount that catalyzes the release of 1
nmol Pi from phosphorylase a per min at 30uC.
Real time PCR (qRT-PCR) experiments
Total RNA were isolated form HCT 116 p53 +/+ cells (a
generous gift from B. Vogelstein) treated with 400nM and 1
microM Etoposide, 0.6 mg/ml Doxorubicin, 10nM Paclitaxel
(Taxol), 100nM UCN-01, 15 mM PD98059 for 8 hours. After
DNAse treatment, reverse transcription was performed with 20 mg
of mRNA using MMLV reverse transcriptase (Promega) and oligo
dT primer according to the manufacturer’s recommendations
QRT- PCR experiments were carried out using SYBRH Green
PCR Master Mix (Applied Biosystems, USA). Reaction mixtures
contained: 5 ml cDNA sample (1/10 dilution RT product), 1.5 ml
primer mix (sense and antisense, 0.6 mM final concentration), and
12.5 mlS Y B R H GreenPCR MasterMix.The finalvolumeshouldbe
25 ml. The following primers were used to amplify regions: LATS2
forward 59- AACAGCCTCAACGTGGACCTGTATGAA-39 and
reverse 59-CAGGGCATGCTCCTCCTTGGCGTCGAA- 39;
PTEN forward 59-CAGAAAGACTTGAAGGCGTAT-39 and
reverse 59- GTAACGGCTGAGGGAACT C-39;R B 1f o r w a r d5 9-
TCTGCATTGGTGCTAAAAGTTTCTTGGA-39 and reverse 59-
CCTGTTCTGACCTCGCCTGGGTGTTCGA- 39; MAP4 for-
ward 59-TGATCCCTTTAAGATGTACCATGATGAT-39and re-
verse 59-AATGCTTGTGCTGGTGGCCTCTCTTCTG-39 and
b-actine forward 5 -AGGCCAACCGCGAGAAGATGAC-3 and
reverse 5 -GAAGTCCAGGGCGACGTAGCA-39. The samples
were amplified according to the following protocol: 10 min 95uC, 50
cycles: 15 sec 95uC, 30 sec 56uC–62uC (depending on the primer),
1m i n7 2 uC. Then in order to get the dissociation curve, a stage was
added: 15 sec 95uC, 15 sec 60uC and 15 sec 95uC.
The normalized values were analyzed using SDS2.2.2 program
(Applied Biosystems, USA). All samples were measured in
duplicates and the right formation of the products was verified
by 1% agarose gel electrophoresis (data not shown).
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